Daskal Ilan sold $2.0M of VIAV

Verizon expanded its 6G Innovation Forum (6GIF) with nine new partners, including AWS, Cisco, Intel, and Nvidia, to advance AI-native 6G technologies. The telco has conducted successful ISAC field trials with Samsung and Qualcomm, exploring use cases like crowd-density detection and drone safety tracking. Verizon aims to scale 5G-Advanced capabilities and enable AI workloads, with plans to demonstrate technologies at the 2028 Summer Olympics in Los Angeles.

Viavi Solutions (VIAV) shares fell 17.2% since its last earnings report, despite Q4 fiscal 2026 results beating estimates. Revenue rose 52.5% YoY to $443.1M, driven by data center and aerospace/defense demand. Non-GAAP EPS was $0.34 vs. $0.30 expected. The company guided Q1 FY2027 revenue to $450M-$460M and EPS to $0.40-$0.42. Analysts revised estimates upward by 47.67% in the past month.

Viavi Solutions (down 10.9%) had the fastest revenue growth among inspection instruments stocks, while Badger Meter (NYSE:BMI, down 9.3%) reported a 6.6% revenue decline. Itron (NASDAQ:ITRI, up 12.2%) missed revenue estimates but exceeded EBITDA and EPS guidance. Teledyne (NYSE:TDY, down 3.7%) reported a 9.8% revenue increase, beating expectations. Market risks have shifted from AI to geopolitics and back to fundamentals.

Viavi Solutions (NASDAQ: VIAV) shares rose about 11% in the afternoon after the company announced Vertex 6.0, a channel emulator for 6G and Wi-Fi 7/8 testing. Viavi said the platform recreates real-world wireless conditions in a lab and follows an upgrade to its Vertex line after acquiring related channel emulation assets from Spirent. The stock is up 138% YTD but 22% below its 52-week high.

VIAVI Solutions (VIAV) shares rose 9.68% to $42.12 on Wednesday after the company launched Vertex 6.0, an enhanced channel emulation platform for 6G and Wi-Fi 7/8 testing. VIAV said the platform provides 400 MHz instantaneous bandwidth and supports carrier frequencies up to 23.6 GHz, with added RF testing capabilities.

Viavi Solutions shares rose 8.9% to $41.83 after five analyst updates. Stifel and Rosenblatt kept Buy ratings with targets of $65 and $70. B. Riley and Needham kept Buy but cut targets to $60. UBS maintained Neutral and cut its target to $44. Average target fell to $60.